BiOrion is a Dutch clinical stage biopharmaceutical drug discovery company engaged in developing targeted therapeutics and companion imaging diagnostics for fibrotic diseases. We are currently developing a PET-imaging diagnostic for liver fibrosis and a combined PET-imaging diagnostic and targeted radiotherapeutic for advanced CMS4 colon cancer. Our platform and drug development engine is based on proprietary PDGF-ß-receptor medium affinity binding bicyclic peptides and PDGF-ß-receptor high affinity VHH nanobodies.

Read more


Fibrotic tissue, as present in liver fibrosis and in mesenchymal type colon cancer stroma, is characterized by abundant myofibroblast-specific overexpression of the PDGF-ß-receptor. This over-expressed receptor allows myofibroblast-specific targeting and delivery of antifibrotic drugs, thereby leaving healthy tissues unaffected. After binding of BiOrion’s peptide-conjugate to the receptor, the complex is internalized and accumulated rapidly and, dependent on the payload, can exert its intracellular effect.

Read more


BiOrion runs three active development programs. Hepatoscan®, is a PET imaging diagnostic to identify and stratify patients with hepatic fibrosis. In the imaging diagnostic Oncoloscan®, the PET radionuclide 68Gallium is conjugated to the PDGF-ß-receptor binding VHH nanobody whereas in Oncoluthera ® the PET radionuclide 177Lutetium is conjugated to this VHH nanobody. Both are developed for patients suffering from advanced CMS4 colorectal cancer. Fibroferon®, finaly, is PDGF-ß-receptor targeted C-terminal signaling domain of interferon gamma. Fibroferon® is primarily developed for targeted antifibrotic therapy of patients suffering from hepatic fibrosis.

Read more

Selective Targeting of Fibrotic stroma

allowing precise PET radio-imaging and radiotherapy of mesenchymal type colon cancer


More News >>


no event